Involvement of Inducible 6-Phosphofructo-2-kinase in the Anti-diabetic Effect of Peroxisome Proliferator-activated Receptor γ Activation in Mice

Xin Guo†, Kefeng Xu†, Jifeng Zhang†, Honggui Li†, Weiyu Zhang†, Huan Wang†, Alex J. Lange**, Y. Eugene Chen†‡, Yuqing Huo††‡, and Chaodong Wu†‡‡

From the †Intercollegiate Faculty of Nutrition, Department of Nutrition and Food Science, Texas A&M University, College Station, Texas 77843, the ‡Cardiovascular Research Institute, Morehouse School of Medicine, Atlanta, Georgia 30310, the §Cardiovascular Center, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48105, the Departments of †Medicine and **Biochemistry, Molecular Biology, and Biophysics, University of Minnesota Medical School, Minneapolis, Minnesota 55455, and the ‡‡Institute of Molecular Medicine, Peking University, Beijing 100871, China

PKF2B3 is the gene that codes for the inducible isoform of 6-phosphofructo-2-kinase (iPFK2), a key regulatory enzyme of glycolysis. As one of the targets of peroxisome proliferator-activated receptor γ (PPARγ), PKF2B3/iPFK2 is up-regulated by thiazolidinediones. In the present study, using PKF2B3/iPFK2-disrupted mice, the role of PKF2B3/iPFK2 in the anti-diabetic effect of PPARγ activation was determined. In wild-type littermate mice, PPARγ activation (i.e. treatment with rosiglitazone) restored euglycemia and reversed high fat diet-induced insulin resistance and glucose intolerance. In contrast, PPARγ activation did not reduce high fat diet-induced hyperglycemia and failed to reverse insulin resistance and glucose intolerance in PKF2B3−/− mice. The lack of anti-diabetic effect in PKF2B3−/− mice was associated with the inability of PPARγ activation to suppress adipose tissue lipolysis and proinflammatory cytokine production, stimulate visceral fat accumulation, enhance adipose tissue insulin signaling, and appropriately regulate adipokine expression. Similarly, in cultured 3T3-L1 adipocytes, knockdown of PKF2B3/iPFK2 lessened the effect of PPARγ activation on stimulating lipid accumulation. Furthermore, PPARγ activation did not suppress inflammatory signaling in PKF2B3/iPFK2-knockdown adipocytes as it did in control adipocytes. Upon inhibition of excessive fatty acid oxidation in PKF2B3/iPFK2-knockdown adipocytes, PPARγ activation was able to significantly reverse inflammatory signaling and proinflammatory cytokine expression and restore insulin signaling. Together, these data demonstrate that PKF2B3/iPFK2 is critically involved in the anti-diabetic effect of PPARγ activation.

Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor whose activation by thiazolidinediones (TZDs) effectively improves systemic insulin sensitivity and lowers plasma glucose levels in both human patients and rodent models of type 2 diabetes (1–8). Because TZDs are effective in liver- or muscle-specific PPARγ-deficient mice (9, 10) but not in adipose tissue-deleted mice (11) and adipose-specific PPARγ-deficient mice (12), adipose tissue has been considered as the primary target site for the anti-diabetic effect of PPARγ activation (13, 14). Further investigations have suggested two adipose tissue-based mechanisms to largely explain the anti-diabetic effect of PPARγ activation (6, 15). In the first mechanism, PPARγ activation by TZDs appropriately alters the expression of adipocyte genes that are involved in lipogenesis and triglyceride synthesis to increase the capacity of fat storage in adipose tissue (16–19). This leads to reduction of the circulating levels of free fatty acids (FFA) and thereby reversal of FFA-induced insulin resistance. In the second mechanism, PPARγ activation by TZDs suppresses the adipose tissue inflammatory response (20, 21) and appropriately regulates adipokine expression (6, 22, 23). This improves adipose tissue function, which in turn brings about the insulin-sensitizing effect (6). However, the molecular link between the two mechanisms remains to be elucidated.

Upon activation of PPARγ, a number of PPARγ target genes are altered to promote fat storage in adipose tissue (16, 24–26). For example, TZDs stimulate the expression of glycerol kinase (GyK), which increases triglyceride synthesis in adipocytes by providing glycerol 3-phosphate as a key substrate (16). Similarly, PPARγ activation stimulates the expression of the cyto-

† This work was supported, in whole or in part, by National Institutes of Health Grants HL78679 and HL080569 (to Y. H.) and HL89544, and HL75397 (to Y. E. C.). This work was also supported by American Diabetes Association Grants 1-10-BS-76 (to Y. H.) and 1-10-JF-54 (to C. W.).

‡ The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1 and S2.

§ Supported by American Heart Association National Career Development Grant 0835237N.

¶ An established investigator of the American Heart Association (Grant 0840025N). To whom correspondence may be addressed: 1150 W. Medical Center Dr., MSRB III 7301E, Ann Arbor, MI 48015. Fax: 734-936-2641; E-mail: echenum@med.umich.edu.

∥ To whom correspondence may be addressed: 420 Delaware St. SE, MMC508, Minneapolis, MN 55455. Fax: 612-626-4411; E-mail: yuqing@umn.edu and Institute of Molecular Medicine, Peking University, Beijing 100871, China.

* To whom correspondence may be addressed: 2253 TAMU, College Station, TX 77843. Fax: 979-862-7782; E-mail: cdwu@tamu.edu.

** To whom correspondence may be addressed: 420 Delaware St. SE, MMC508, Minneapolis, MN 55455. Fax: 612-626-4411; E-mail: yuqing@umn.edu.

†† Supported by American Heart Association National Career Development Grant 0835237N.

‡‡ Supported by American Heart Association National Career Development Grant 0840025N. To whom correspondence may be addressed: 1150 W. Medical Center Dr., MSRB III 7301E, Ann Arbor, MI 48015. Fax: 734-936-2641; E-mail: echenum@med.umich.edu.

§§ To whom correspondence may be addressed: 420 Delaware St. SE, MMC508, Minneapolis, MN 55455. Fax: 612-626-4411; E-mail: yuqing@umn.edu and Institute of Molecular Medicine, Peking University, Beijing 100871, China.
involvement of iPFK2 in the effect of PPARγ activation

**FIGURE 1.** Disruption of PFKFB3/iPFK2 blunts the anti-diabetic effect of PPARγ activation. Male PFKFB3+/− mice and wild-type littermates, at the age of 5–6 weeks, were fed an HFD for 12 weeks and treated with rosiglitazone (10 mg/kg/day) or vehicle (PBS) during the last 4 weeks of HFD feeding. Data are means ± S.E. (error bars), n = 6. A, changes in the levels of plasma glucose. As the control, the age-matched male PFKFB3+/− mice and wild-type littermates were fed a low fat diet (LFD) and received no treatment. All of the mice were fasted for 4 h before collection of blood samples. **, p < 0.01, rosiglitazone versus vehicle within the same genotype. †, p < 0.05; ††, p < 0.01, PFKFB3+/− versus wild type on an HFD with the same treatment (rosiglitazone or vehicle). For B and C, mice were fasted for 4 h and received an intraperitoneal injection of D-glucose (2 g/kg) (B) or insulin (0.5 units/kg) (C). *, p < 0.05; **, p < 0.01, wild type/rosiglitazone versus wild type/vehicle. †, p < 0.05; ††, p < 0.01, PFKFB3+/−/rosiglitazone versus wild type/rosiglitazone. B, glucose tolerance test. C, insulin tolerance test. D, changes in the levels of plasma insulin. Mice were fed and/or treated as described in A. Statistical analyses were identical to those in A.

solic isomerase of phosphoenolpyruvate carboxykinase (PEPCK) in adipocytes (24, 25). This increases glyceroneogenesis and provides another way to synthesize glycerol 3-phosphate and consequently triglycerides in adipocytes/adipose tissue (27, 28). At this point, although the stimulatory effect of PPARγ activation on GyK and PEPCK expression is increasingly documented, the involvement of GyK and/or PEPCK in the anti-diabetic effect of PPARγ activation is increasingly recognized through JNK1 and NF-κB pathways to suppress adipocyte inflammatory response (36). How- ever, the extent to which PFKFB3/iPFK2 participates in the in vivo effects of PPARγ activation is not known. Using PFKFB3/iPFK2-disrupted mice, the present study demonstrates that PFKFB3/iPFK2 is involved in the anti-diabetic effect of PPARγ activation, probably by increasing the ability of adipose tissue to store fat and by suppressing adipose tissue inflammatory response. In addition, the mechanisms underlying the involvement of PFKFB3/iPFK2 in the effects of PPARγ activation are explored in cultured 3T3-L1 adipocytes.

**EXPERIMENTAL PROCEDURES**

**Animal Experiments—Because homozygous disruption of PFKFB3/iPFK2 is embryonic lethal (35), PFKFB3+/− mice, provided by Drs. Telang and Chesney (University of Louisville), were generated as described previously (35) and used for the present study. Considering that rosiglitazone lowers the levels of plasma glucose and improves systemic insulin sensitivity only in diabetic mice, male PFKFB3+/− and wild-type littermates (C57BL/6J background) were fed a high fat diet (HFD) prior to treatment with rosiglitazone. It has been recently shown that feeding an HFD to PFKFB3+/− mice exacerbates systemic insulin resistance and adipose tissue inflammatory response (36). Briefly, all mice were maintained as previously described (36). At the age of 5–6 weeks, mice were fed an HFD (60% fat calories, 20% protein calories, and 20 carbohydrate calories) (Research Diets, Inc., New Brunswick, NJ) for 12 weeks. During the last 4 weeks of the feeding regimen, HFD-fed mice were treated with rosiglitazone (10 mg/kg/day in PBS; Avandia tablets) or vehicle (PBS) via oral gavages. As the control, the age-matched male mice were fed a low fat diet (10% fat calories, 20% protein calories, and 70% carbohydrate calories) and received no treatment. The composition of both HFD and low fat diet has been described previously (36). Body weight and food intake of the mice were recorded every 4 days during the 12-week feeding period. At the end of the feeding/treatment regimen, mice were fasted for 4 h before sacrifice for collection of blood and
tissue samples as described previously (36–39). Visceral fat content was estimated as the sum of epididymal, mesenteric, and perinephric fat depots (36, 38). After weighing, lipolysis rates were determined on adipose tissue samples. Some tissue samples were either fixed and embedded for histological analyses or frozen in liquid nitrogen and then stored at −80 °C for further analyses. Some mice were fasted similarly and used for glucose and insulin tolerance tests. For a separate study to analyze the role of PPARγ in regulating PFKFB3 expression, PPARγ2−/− mice and their wild-type littermates were generated as described before (40) and used for adipose tissue sample collection and embryonic fibroblast isolation (see below). All study protocols were reviewed and approved by the Institutional Animal Care and Use Committees of Texas A&M University and the University of Michigan.

Measurement of Metabolite and Hormone Levels—The levels of plasma metabolites, such as glucose, triglycerides, and FFA, were measured using metabolic assay kits (Sigma and BioVision (Mountain View, CA)). The levels of plasma hormones (i.e. insulin and leptin) were measured using enzyme-linked immunosorbent assay kits (Crystal Chem Inc., Downers Grove, IL). The levels of adipose tissue fructose 2,6-bisphosphate (F26P2) were determined using the 6-phosphofructo-1-kinase activation method as described previously (39).

Glucose and Insulin Tolerance Tests—The assays were conducted as previously described (39). After fasting for 4 h, mice received a peritoneal injection of D-glucose (2 g/kg) or insulin (0.5 unit/kg) (Humulin, Lilly).

Measurement of Adipose Tissue Lipolysis—The assays were conducted as described previously (36, 41, 42). Briefly, freshly isolated adipose tissue samples were washed several times with PBS and incubated in a final volume of 1 ml of high glucose Dulbecco’s modified Eagle’s medium containing 2% fatty acid-free bovine serum albumin in the presence or absence of 10 μM isoproterenol at 37 °C for 3 h. Aliquots of the medium were sampled hourly to quantify glycerol content using metabolic kits (BioVision, Mountain View, CA). The rate of lipolysis was estimated as the efflux of glycerol.

Histological Analyses of Adipose Tissue—The paraffin-embedded adipose tissue blocks were cut into sections of 5-μm thickness and stained with hematoxylin and eosin.

Cell Culture and Treatment—3T3-L1 cells were maintained in high glucose Dulbecco’s modified Eagle’s medium and differentiated in induction medium for 6–8 days as described previously (36). To clarify the role of PPARα activation in stimulating PFKFB3 expression, differentiated 3T3-L1 cells were treated with a PPARα agonist, Wy14643 (10 μM) or GW7647 (0.1 μM); a dual agonist of PPARα and PPARδ, GW0742 (0.2 μM); a PPARδ agonist, GW501516 (0.2 μM); a PPARγ agonist, GW7845 (0.2 μM) or rosiglitazone (1 μM); or vehicle (0.1% DMSO) for 24 h and har-

![FIGURE 2. Disruption of PFKFB3/iPFK2 impairs the response of adipose tissue PFKFB3/iPFK2 but not other PPARγ target genes to PPARγ activation. At the age of 5–6 weeks, male PFKFB3+/− mice and wild-type littermates were fed an HFD for 12 weeks and treated with rosiglitazone (10 mg/kg/day) or vehicle (PBS) during the last 4 weeks of HFD feeding. At the end of the feeding/treatment regimen, mice were fasted for 4 h before collection of tissue samples. Epididymal adipose tissue samples were used for the analyses. A, the mRNA levels of PFKFB3 were measured using real-time RT-PCR. B, adipose tissue iPFK2 was determined using Western blot. C, adipose tissue F26P2 levels were determined using the 6-phosphofructo-1-kinase activation method. D, representative PCR products of adipose tissue genes. E, quantification of the expression of adipose tissue genes. Rosi, rosiglitazone. For A, C, and D, data are means ± S.E. (error bars), n = 6. *, p < 0.05; **, p < 0.01; Rosi, rosiglitazone versus vehicle within the same genotype (in A and C) or wild type/vehicle versus wild type and PFKFB3+/−/rosiglitazone versus PFKFB3+/−/vehicle for the same gene (in E). †, p < 0.05; ††, p < 0.01; PFKFB3+/− versus wild type with the same treatment (rosiglitazone or vehicle in A and C).]
Involvement of iPFK2 in the Effect of PPARγ Activation

vested for further analyses. In addition, mouse embryonic fibroblast cells were isolated from PPARγ2−/− mice and PPARγ2−/+ mice and treated with retrovirus containing the cDNA of PPARγ1, PPARγ2, or control as described previously (40). The treated mouse embryonic fibroblast cells were then harvested to determine changes in the mRNA levels of PFKFB3. Using a PFKFB3 promoter-luciferase construct, the effect of PPARγ overexpression on activating PFKFB3 promoter was determined by the luciferase assay as described by Cao et al. (43). To explore the direct role of PFKFB3/iPFK2 in modulating the effect of PPARγ activation, stable PFKFB3/iPFK2-knockdown (iPFK2-KD) 3T3-L1 cells and control (iPFK2-Ctrl) 3T3-L1 cells were used. These cells have been previously established (36). During the last 48 h of differentiation, both iPFK2-KD and iPFK2-Ctrl adipocytes were treated with rosiglitazone (1 μM) or vehicle (0.1% DMSO) and used to quantify the expression of PPARγ target genes as well as for further analyses using the methods described below.

To quantify adipocyte lipid content, the cells were stained with Oil Red O. The lipid-associated dye was extracted with isopropyl alcohol for 15 min. The OD of the extraction solution was measured using a spectrophotometer at 510 nm (40). To determine the rate of glucose incorporation into lipid, each well was measured using a Beckman liquid scintillation counter. To analyze adipocyte inflammatory response and insulin signaling, the cells were incubated with palmitate (250 μM) or vehicle (0.5% bovine serum albumin) for 24 h. Cell lysates were then prepared and used for Western blots to measure the levels and phosphorylation states of JNK, phospho-JNK, Akt1/2, and phospho-Akt (Ser473) using Western blots. The sections of epididymal fat pad were stained with hematoxylin and eosin.

FIGURE 3. Disruption of PFKFB3/iPFK2 lessens the effect of PPARγ activation on increasing adipose tissue fat storage. At the age of 5–6 weeks, male PFKFB3−/− mice and wild-type littermates were fed an HFD for 12 weeks and treated with rosiglitazone (10 mg/kg/day) or vehicle (PBS) during the last 4 days of HFD feeding. At the end of the feeding/treatment regimen, mice were fasted for 4 h before collection of tissue samples. For A and B, data are means ± S.E. (error bars), n = 6. *, p < 0.05; ††, p < 0.01, PFKFB3−/− versus wild type with the same treatment (in A and B, rosiglitazone or vehicle) in the presence of the same condition (in A, basal or isoproterenol), A, the rates of adipose tissue lipolysis were measured under both basal and isoproterenol-stimulated conditions. B, visceral fat content was estimated from the sum of epididymal, mesenteric, and perinephric fat mass. C, adipose tissue histology. The sections of epididymal fat pad were stained with hematoxylin and eosin.

RESULTS

Disruption of PFKFB3/iPFK2 Blunts the Anti-diabetic Effect of PPARγ Activation—After a feeding of an HFD, wild-type littersmates exhibited insulin resistance, glucose intolerance, and hyperglycemia. In these wild-type mice, treatment with rosiglitazone for 4 weeks normalized the levels of plasma glucose (169.67 ± 6.05 versus 242.59 ± 6.23 mg/dl, p < 0.01; Fig. 1A) and corrected glucose intolerance and insulin resistance (Fig. 1, B and C) compared with vehicle. Additionally, treatment with rosiglitazone lowered the circulating levels of insulin (Fig. 1D) as well as FFA and triglycerides (Table 1), indicating the
Induction of adipose tissue inflammatory response and on reversal of adipose tissue dysfunction. Additionally, PPAR activation, the response of adipose tissue PFKFB3/iPFK2 to rosiglitazone was determined. Compared with vehicle, rosiglitazone caused a significant decrease in adipose tissue lipolysis and an increase in visceral fat in the mice. In wild-type littermates, treatment with rosiglitazone did not bring about significant decrease in adipose tissue lipolysis and an increase in visceral fat content (Fig. 3, A and B). However, in PFKFB3−/− mice, treatment with rosiglitazone did not bring about significant levels of adipose PFKFB3/iPFK2 in wild-type littermates, confirming the stimulatory effect of PPARγ activation. However, this stimulatory effect was markedly lessened in PFKFB3−/− mice (Fig. 2, A and B). Because PFKFB3/iPFK2 determines the production of F26P2, the levels of adipose tissue F26P2 were quantified to reflect PFKFB3/iPFK2 activity. Consistent with an increase in the mRNA levels of PFKFB3/iPFK2, the levels of adipose tissue F26P2 were significantly higher in rosiglitazone-treated wild-type mice than in vehicle-treated wild-type mice (3.54 ± 0.48 vs. 1.77 ± 0.21 nmol/g, p < 0.05; Fig. 2C). However, in PFKFB3−/− mice, rosiglitazone only caused a slight and insignificant increase in the levels of F26P2 compared with vehicle (1.29 ± 0.29 vs. 0.92 ± 0.08 nmol/g). These data suggest that two intact PFKFB3/iPFK2 alleles are necessary for mice to fully respond to PPARγ activation.

To address whether disruption of PFKFB3/iPFK2 impairs the response of other PPARγ target genes to PPARγ activation, the expression of GyK and PEPCK as well as PPARγ in the adipose tissue was determined. Under the basal condition (treatment with vehicle), the expression of the GyK, PEPCK, and PPARγ in PFKFB3−/− mice did not differ from that in wild-type mice (Fig. 2, D and E). Furthermore, in response to PPARγ activation by rosiglitazone treatment, the expression of GyK and PEPCK in PFKFB3−/−/vehicle mice was increased to an extent comparable with that in wild-type littermates (Fig. 2, D and E). These data indicate that PPARγ expression, PPARγ translocation to cell nuclei, and activation of PPARγ-targeted genes are not disturbed in PFKFB3−/− mice.

**Involvement of iPFK2 in the Effect of PPARγ Activation**

**FIGURE 4.** Disruption of PFKFB3/iPFK2 blunts the effects of PPARγ activation on suppression of HFD-induced adipose tissue inflammatory response and on reversal of adipose tissue dysfunction. At the age of 5–6 weeks, male PFKFB3+/− mice and wild-type littermates were fed an HFD for 12 weeks and treated with rosiglitazone (10 mg/kg/day) or vehicle (PBS) during the last 4 weeks of HFD feeding. At the end of the feeding/treatment regimen, mice were fasted for 4 h before the collection of tissue samples. Rosi, rosiglitazone. A, changes in inflammatory signaling were analyzed using Western blots. B, quantification of inflammatory signaling (arbitrary units). C, changes in adipose mRNA levels of TNFα and IL-6. D, changes in adipose mRNA levels of resistin and adiponectin. For B and D, data are means ± S.E. (error bars), n = 6, *p < 0.05; **p < 0.01, wild type/rosiglitazone versus wild type/vehicle for the same gene. t, p < 0.05; ††, p < 0.01 PFKFB3−/−/vehicle versus wild type/vehicle or PFKFB3−/−/rosiglitazone versus wild type/rosiglitazone for the same gene. For C and D, the expression of adipose tissue genes was measured using real-time RT-PCR. E, adipose tissue insulin signaling was analyzed using Western blot. Adipose tissue samples were collected at 5 min after a bolus injection of insulin (1 unit/kg) into the portal vein. P-p54, phospho-p54; P-p46, phospho-p46; P-Akt, phospho-Akt.
Involvement of iPFK2 in the Effect of PPARγ Activation

changes in any of the above parameters. Additionally, the size of epididymal adipocytes was much larger in rosiglitazone-treated wild-type mice than in rosiglitazone-treated PFKFB3−/− mice (Fig. 3C). Together, these data demonstrate that disruption of PFKFB3/iPFK2 lessens the effect of PPARγ activation on increasing adipose tissue fat storage.

Disruption of PFKFB3/iPFK2 Blunts the Effects of PPARγ Activation on Suppression of HFD-induced Adipose Tissue Inflammatory Response and on Reversal of Adipose Tissue Dysfunction—Suppression of adipose tissue inflammatory response is one of the major mechanisms by which PPARγ activation reverses insulin resistance and corrects hyperglycemia (6, 21, 46). The effects of PPARγ activation on adipose tissue inflammatory signaling and proinflammatory cytokine expression were determined. In HFD-fed wild-type littermates, treatment with rosiglitazone brought about a decrease in the phosphorylation of JNK1 and NF-κB p65 (Fig. 4, A and B), which was accompanied by a significant decrease in the mRNA levels of TNFα and IL-6 compared with treatment with vehicle (Fig. 4C). Because suppression of adipose tissue inflammatory response is linked to reversal of adipose tissue dysfunction (6, 47), adipose expression of adipokines and insulin signaling were analyzed. Compared with vehicle, treatment with rosiglitazone caused a decrease in adipose mRNA levels of resistin and an increase in adipose mRNA levels of adiponectin (Fig. 4D) and an increase in insulin-stimulated phosphorylation of Akt (Fig. 4E), all of which contributed to the effects of PPARγ activation on reversal of systemic insulin resistance and on correction of hyperglycemia. However, in PFKFB3−/− mice, treatment with rosiglitazone did not effectively suppress adipose tissue inflammatory signaling and the mRNA levels of TNFα and IL-6 compared with treatment with vehicle (Fig. 4, A–C). Additionally, treatment with rosiglitazone did not appropriately alter adipose expression of resistin and adiponectin as it did in wild-type mice (Fig. 4D) and failed to increase insulin-stimulated phosphorylation of Akt (Fig. 4E). Collectively, these data demonstrate that disruption of PFKFB3/iPFK2 blunts the effects of PPARγ activation on suppressing HFD-induced adipose inflammatory response and on reversing adipose tissue dysfunction.

Knockdown of PFKFB3/iPFK2 Lessens the Effect of PPARγ Activation on Stimulating Adipocyte Lipid Accumulation—The direct role of PFKFB3/iPFK2 in modulating the effect of PPARγ activation on lipid accumulation was explored in iPFK2-KD and iPFK2-Ctrl 3T3-L1 adipocytes. Compared with that in iPFK2-Ctrl cells, the amount of iPFK2 was low and was not increased by rosiglitazone treatment in iPFK2-KD adipocytes (Fig. 5A). Under the basal condition (treatment with vehicle), iPFK2-KD adipocytes accumulated less lipid than did iPFK2-Ctrl adipocytes (Fig. 5, B and C), which was attributed to a decrease in the rate of glucose incorporation into lipid (Fig. 5D). After treatment with rosiglitazone, iPFK2-KD adipocytes exhibited a much smaller increase in lipid accumulation and the rate of glucose incorporation into lipid than did iPFK2-Ctrl adipocytes. This occurred where the response of GyK and PEPCK to PPARγ activation in iPFK2-KD adipocytes was comparable with that in iPFK2-Ctrl adipocytes (supplemental Fig. S2), indicating the importance of PFKFB3/iPFK2 to the effect of PPARγ activation on stimulating adipocyte lipid accumulation. These data, consistent with those observed in rosiglitazone-treated PFKFB3−/− mice, demonstrate that adipocyte PFKFB3/iPFK2 is needed, at least in part, for PPARγ activation to increase adipose tissue fat storage.

Knockdown of PFKFB3/iPFK2 Diminishes the Effects of PPARγ Activation on Suppression of Adipocyte Inflammatory Response and on Improvement of Adipocyte Function—The direct role of PFKFB3/iPFK2 in modulating the effects of PPARγ activation on adipocyte inflammatory response and on adipocyte function was explored. In iPFK2-Ctrl adipocytes, treatment with rosiglitazone caused a significant decrease in palmitate-stimulated phosphorylation of JNK1 and NF-κB p65 (Fig. 6, A and B), which was accompanied by a decrease in the mRNA levels of TNFα and IL-6 (Fig. 6C). In contrast, treatment of iPFK2-KD adipocytes with rosiglitazone did not effectively bring about a significant decrease in palmitate-stimulated phosphorylation of JNK1 and NF-κB p65 and failed to suppress the mRNA levels of TNFα and IL-6 (Fig. 6C). These data, along with those observed in rosiglitazone-treated PFKFB3−/− mice, suggest that the intact PFKFB3/iPFK2 in adipocytes is needed, at least in part, for PPARγ activation to suppress adipose tissue inflammatory response.

Increased inflammatory response contributes to inappropriate expression of adipokines and decreased insulin signaling in adipocytes (36). To analyze the direct involvement of PFKFB3/iPFK2 in the effect of PPARγ activation on adipocyte function, the mRNA levels of resistin and adiponectin as well as insulin signaling were determined in rosiglitazone- or vehicle-treated iPFK2-KD and iPFK2-Ctrl adipocytes. Compared with vehicle,
Involvement of iPFK2 in the Effect of PPARγ Activation

FIGURE 6. Knockdown of PFKFB3/iPFK2 diminishes the effects of PPARγ activation on both suppression of adipocyte inflammatory response and improvement of adipocyte function. After differentiation for 6–8 days, stable iPFK2-KD and iPFK2-Ctrl adipocytes were treated with rosiglitazone (Rosi; 1 μM) or vehicle (0.1% DMSO) for 48 h in the presence or absence of palmitate (Pal; 250 μM) for the last 24 h. Thereafter, the treated cells were subjected to the assays described under “Experimental Procedures.” A, changes in inflammatory signaling were analyzed using Western blots. For B–D, data are means ± S.E., n = 4. B, quantification of inflammatory signaling (arbitrary units). Left, phospho-JNK1 (p-JNK1)/JNK1; right, phospho-p46 (p-p46).**, p < 0.01, iPFK2-Ctrl treated with Rosi versus iPFK2-Ctrl treated without Rosi in the presence or absence of Pal. ††, p < 0.01, iPFK2-KD versus iPFK2-Ctrl under the same condition. For C and D, the expression of proinflammatory cytokines (C) and adipokines (D) was measured using real-time RT-PCR. *, p < 0.05, iPFK2-Ctrl/vehicle versus iPFK2-Ctrl/vehicle for the same gene. ††, p < 0.01, iPFK2-KD/vehicle versus iPFK2-KD/vehicle or iPFK2-Ctrl/vehicle versus iPFK2-Ctrl/vehicle for the same gene. E, adipocyte insulin signaling was analyzed using Western blot. Before harvest, the cells were incubated with or without insulin (100 nM) for 30 min. P-p46, phospho-p46.

PFKFB3/iPFK2-knockdown-associated increase in ROS production blunts the beneficial effects of PPARγ activation in iPFK2-KD adipocytes. Next, we determined the extent to which correction of excessive ROS production restores the effects of PPARγ activation on inflammatory response and insulin signaling in iPFK2-KD adipocytes. Upon inhibition of fatty acid oxidation by etomoxir, palmitate-stimulated ROS production in iPFK2-KD adipocytes was decreased to a level comparable with that in untreated iPFK2-Ctrl adipocytes (Fig. 7B). Under this condition, treatment with rosiglitazone brought about a decrease in the phosphorylation of JNK1 and NF-κB p65 as well as the mRNA levels of TNFα and IL6 in iPFK2-KD adipocytes to their respective levels comparable with those in rosiglitazone-treated iPFK2-Ctrl adipocytes (Fig. 7, C and D). These effects did not occur in iPFK2-KD adipocytes in the absence of etomoxir (see above; Fig. 6, A–C). Additionally, upon supplementation of etomoxir, treatment with rosiglitazone increased the phosphorylation of Akt in iPFK2-KD adipocytes in the presence of palmitate (Fig. 7E), which was also not observed in iPFK2-KD adipocytes incubated without etomoxir (see above; Fig. 6E). Collectively, these data suggest that inhibition of excessive fatty acid oxidation restores the effects of PPARγ activation on both suppression of adipocyte inflammatory response and stimulation of adipocyte insulin signaling in iPFK2-KD adipocytes.

DISCUSSION

PFKFB3/iPFK2 has been identified as a target gene of PPARγ since the finding that troglitazone, an early TZD, increases PFKFB3/iPFK2 expression in adipocytes (33, 34). In the present study, two lines of evidence were obtained to further demonstrate the role of PPARγ in controlling PFKFB3/iPFK2 expression. Notably, disruption of PPARγ2 decreased PFKFB3/iPFK2 expression, whereas PPARγ2 overexpression rescued this defect. In addition, agonist(s) for PPARγ but not PPARα and/or PPARδ stimulated the expression of adipocyte PFKFB3/iPFK2, which was attributed to transcription activation of the promoter of PFKFB3. Interestingly, the metabolic phenotype of PFKFB3/iPFK2-disrupted mice (36) was similar to that of PPARγ2-disrupted mice (40) and adipose tissue-specific PPARγ-knock-out mice on an HFD (12). This leads to the hypothesis that PFKFB3/iPFK2 is critically involved in the antidiabetic effect of PPARγ activation. To test this hypothesis, using PFKFB3/iPFK2-disrupted mice and PFKFB3/iPFK2-
Involvement of iPFK2 in the Effect of PPARγ Activation

knockdown 3T3-L1 adipocytes, the present study determined the extent to which PFKFB3/iPFK2 accounts for the anti-diabetic effect of PPARγ activation.

PFKFB3/iPFK2 is involved in the effect of PPARγ activation on increasing adipose tissue fat storage. Notably, rosiglitazone-stimulated adipocyte lipid accumulation, due largely to an increase in glucose incorporation into lipid, is positively correlated with the amount of PFKFB3/iPFK2. In our previous study, we have demonstrated that PFKFB3/iPFK2 increases adipose tissue/adipocyte fat accumulation by stimulation of glycolysis-derived lipogenesis and triglyceride synthesis (36). In the present study, rosiglitazone failed to increase adipose tissue fat storage in PFKFB3+/- mice, which indicates the importance of PFKFB3/iPFK2 to the effect of PPARγ activation on fat storage. In addition to PFKFB3/iPFK2, GyK and PEPCK are also upregulated in response to PPARγ activation in adipocytes (16, 24, 25). The role of these two enzymes in participation of PPARγ activation-mediated fat storage has been speculated. In PFKFB3+/- mice, the response of adipose GyK and PEPCK to rosiglitazone remained intact, suggesting a normal activation of adipose tissue PPARγ in the presence of PFKFB3/iPFK2 disruption. However, the normal response of GyK

FIGURE 7. Inhibition of fatty acid oxidation restores the effects of PPARγ activation on both suppression of adipocyte inflammatory response and stimulation of adipocyte insulin signaling. After differentiation for 6 – 8 days, stable iPFK2-KD and iPFK2-Ctrl adipocytes were treated with rosiglitazone (Rosi; 1 μM) or vehicle (0.1% DMSO) for 48 h. In the last 24 h, the cells were incubated with or without etomoxir (Eto; 100 μM) in the presence or absence of palmitate (Pal; 250 μM) for 24 h. Thereafter, the treated cells were subjected to the assays described under “Experimental Procedures.” For A and B, the production of ROS was measured using the nitro blue tetrazolium assay. Data are means ± S.E. (error bars), n = 4. †, p < 0.01, iPFK2-KD in the presence of palmitate versus iPFK2-KD in the absence of palmitate under treatment with rosiglitazone. ‡, p < 0.05, iPFK2-KD versus iPFK2-Ctrl in the absence of etomoxir; ††, p < 0.05, iPFK2-KD in the presence of etomoxir versus iPFK2-KD in the absence of etomoxir. C, changes in adipocyte expression of proinflammatory cytokines. Data are means ± S.E. (error bars), n = 4. †, p < 0.05, iPFK2-KD/etomoxir/DMSO versus iPFK2-KD/vehicle (Veh)/DMSO for the same gene. ††, p < 0.01, iPFK2-KD/etomoxir/vehicle versus iPFK2-KD/vehicle/DMSO; *, p < 0.05, iPFK2-KD/vehicle/etomoxir/vehicle versus iPFK2-KD/vehicle/etomoxir/DMSO. D, changes in adipocyte insulin signaling. Before harvest, the cells were incubated with or without insulin (100 nM) for 30 min.

FIGURE 8. Involvement of PFKFB3/iPFK2 in the effects of PPARγ activation in adipocytes. Under the condition of overnutrition (A), adipocytes exhibit an increase in inflammatory response, which is brought about at least in part by excessive fatty acid oxidation. Upon activation of PPARγ (B), an increase in the expression of PFKFB3/iPFK2 enhances glycolysis to facilitate the synthesis of triglycerides via generating glycerol-3-phosphate and FFA (derived from acetyl-CoA following pyruvate oxidation). As a result, an increase in channeling FFA to triglyceride synthesis reduces fatty acid oxidation-associated production of ROS, thereby suppressing inflammatory signaling pathways through JNK1 and NF-κB and decreasing the expression of proinflammatory cytokines. DHAP, dihydroxyacetone phosphate; GLUT4, glucose transporter 4; FATP, fatty acid transport protein.
and PEPCK to rosiglitazone in PFKFB3+/− mice was not sufficient to compensate for the PFKFB3/iPFK2 disruption-associated decrease in the ability of adipose tissue to store fat. A possible explanation directly linked to the biochemical properties of these enzymes is that PFKFB3/iPFK2 generates both acetyl-CoA and glycerol 3-phosphate as the required substrates for lipogenesis and triglyceride synthesis in adipocytes (36), whereas GyK and PEPCK appear to only generate glycerol 3-phosphate via direct phosphorylation of glycerol (16) and through glyceroneogenesis (17), respectively. Also, it is possible that the stimulatory effects of GyK and PEPCK on adipocyte/adipose tissue fat storage were offset by the PFKFB3/iPFK2 disruption-associated increase in adipose tissue fatty acid oxidation, given that PFKFB3/iPFK2 has an indirect effect on suppression of adipocyte fatty acid oxidation (36). Based on the current data, the possibility that PFKFB3/iPFK2 disruption generated an environment that could not allow GyK and/or PEPCK to stimulate fat storage cannot be ruled out and will be investigated by future study.

The contribution of PFKFB3/iPFK2 to the anti-diabetic effect of PPARγ activation is also attributable to the suppressive effect of PFKFB3/iPFK2 on adipocyte inflammatory response. Treatment with rosiglitazone brought about a decrease in HFD-stimulated adipose mRNA levels of TNFα and IL-6 in wild-type mice but not in PFKFB3+/− mice. Further, a direct role for PFKFB3/iPFK2 in mediating the anti-inflammatory effect of PPARγ activation was confirmed in a cell culture system. In PFKFB3/iPFK2-knockdown 3T3-L1 adipocytes, rosiglitazone did not decrease palmitate-induced mRNA levels of TNFα and IL-6 as it did in control adipocytes. This PFKFB3/iPFK2-knockdown-associated defect resulted in an inefficiency of rosiglitazone to decrease adipose resistin mRNA levels and to increase adiponectin mRNA levels in both PFKFB3+/− mice and PFKFB3/iPFK2-knockdown adipocytes, which indicated adipose tissue/adipocyte dysfunction (47–49) and contributed to the lack of anti-diabetic effect in rosiglitazone-treated PFKFB3+/− mice.

In the adipose tissue, both macrophages and adipocytes are key determinants of overnutrition-induced adipose tissue inflammatory response (50–53). Attention has been increasingly paid to the effect of PPARγ activation on suppression of the proinflammatory function of macrophages (21, 54, 55). Considering the importance of adipocyte PPARγ activation to whole-body insulin sensitivity (8), the present study focused on the effect of PPARγ activation on adipocyte inflammatory response. We observed that treatment with rosiglitazone effectively reduced the phosphorylation of JNK1 and NF-κB p65 in control adipocytes but not in PFKFB3/iPFK2-knockdown adipocytes. This is consistent with the observation that rosiglitazone blunted palmitate-induced ROS production in control adipocytes but not in PFKFB3/iPFK2-knockdown adipocytes. When PFKFB3/iPFK2 disruption-associated excessive fatty acid oxidation was brought down with etomoxir treatment, rosiglitazone was able to decrease inflammatory response and stimulate insulin signaling in PFKFB3/iPFK2-knockdown adipocytes. Clearly, PFKFB3/iPFK2 contributes to the anti-inflammatory effect of PPARγ activation through a mechanism involving suppression of excessive fatty acid oxidation in adipocytes.

In conclusion, the present study provides data to support the involvement of PFKFB3/iPFK2 in the anti-diabetic effect of PPARγ activation. This role of PFKFB3/iPFK2 is evidenced by the fact that the intact PFKFB3/iPFK2 allows rosiglitazone to increase fat storage in the adipocytes/adipose tissue and to suppress adipocyte/adipose tissue inflammatory response. Mechanistically, the way by which PFKFB3/iPFK2 links two adipose tissue-based mechanisms underlying the anti-diabetic effect of PPARγ activation is attributable to the effect of PFKFB3/iPFK2 on regulating adipocyte lipogenesis and triglyceride synthesis as well as adipocyte fatty acid oxidation-related ROS production and inflammatory response (Fig. 8). These results indicate that selective activation of adipocyte PFKFB3/iPFK2 may be a viable approach to generating the beneficial effects of PPARγ activation in the treatment of type 2 diabetes.

REFERENCES

1. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkinson, W. O., Wilson, T. M., and Kliewer, S. A. (1995) J. Biol. Chem. 270, 12953–12956
2. Berger, J., Bailey, P., Biswas, C., Cullinan, C. A., Doebber, T. W., Hayes, N. S., Saperstein, R., Smith, R. G., and Leibowitz, M. D. (1996) Endocrinology 137, 4189–4195
3. Lebovitz, H. E., Dole, J. F., Patwardhan, R., Rappaport, E. B., and Freed, M. I. (2001) J. Clin. Endocrinol. Metab. 86, 280–288
4. Phillips, L. S., Grunberger, G., Miller, E., Patwardhan, R., Rappaport, E. B., and Saltzman, A. (2001) Diabetes Care 24, 308–315
5. Krentz, A. J., Bailey, C. J., and Melander, A. (2000) BMJ 321, 252–253
6. Evans, R. M., Barish, G. D., and Wang, Y. X. (2004) Nat. Med. 10, 355–361
7. Grundy, S. M. (2006) Nat. Rev. Drug Discov. 5, 295–309
8. Sugli, S., Olson, P., Sears, D. D., Saberi, M., Atkins, A. R., Barish, G. D., Hong, S. H., Castro, G. L., Yin, Y. Q., Nelson, M. C., Hsiao, C., Greaves, D. R., Downes, M., Yu, R. T., Olefsky, J. M., and Evans, R. M. (2009) Proc. Natl. Acad. Sci. U.S.A. 106, 22504–22509
9. Matsusue, K., Haluzik, M., Lambert, G., Yin, S. H., Davrilova, O., Ward, J. M., Brewer, B. Jr., Reitman, M. L., and Gonzalez, F. J. (2003) J. Clin. Invest. 111, 737–747
10. Norris, A. W., Chen, E., Fisher, S. J., Sanuto, I., Ristow, M., Jozsi, A. C., Hirshman, M. F., Rosen, E. D., Goodyear, L. J., Gonzalez, F. J., Spiegelman, B. M., and Kahn, C. R. (2003) J. Clin. Invest. 112, 608–618
11. Chao, L., Marcus-Samuels, B., Mason, M. M., Moitra, J., Vinson, C., Ario- glu, E., Davrilova, O., and Reitman, M. L. (2000) J. Clin. Invest. 106, 1221–1228
12. He, W., Barak, Y., Hevener, A., Olson, P., Liao, D., Le, J., Nelson, M., Ong, E., Olefsky, J. M., and Evans, R. M. (2003) Proc. Natl. Acad. Sci. U.S.A. 100, 15712–15717
13. Kintscher, U., and Law, R. E. (2005) Am. J. Physiol. Endocrinol. Metab. 288, E287–E291
14. Lehrke, M., and Lazar, M. A. (2005) Cell 123, 993–999
15. Qatanani, M., and Lazar, M. A. (2007) Genes Dev. 21, 1443–1455
16. Guan, H. P., Li, Y., Jensen, M. V., Newgard, C. B., Steppan, C. M., and Lazar, M. A. (2002) Nat. Med. 8, 1122–1128
17. Leroyer, S. N., Tordjman, J., Chauvet, G., Quetue, J., Chapron, C., Forest, C., and Antoine, B. (2006) J. Biol. Chem. 281, 13141–13149
18. Kolak, M., Yki-Jarvinen, H., Kannisto, K., Tiikkainen, M., Hamsten, A., Eriksson, P., and Fisher, R. M. (2007) J. Clin. Endocrinol. Metab. 92, 720–724
19. Kershaw, E. E., Schupp, M., Zhu, Y., Misli, S., Yang, Q., and Misli, S. (2007) J. Clin. Endocrinol. Metab. 92, 720–724
20. Wellen, K. E., Tschekir, K., Wiesbrock, S., Yang, Q., Chen, H., and Hotamisligil, G. S. (2004) Endocrinology 145, 2214–2220
21. Stienstra, R., Duval, C., Keshtkar, S., van der Laak, J., Kersten, S., and Muller, M. (2008) J. Biol. Chem. 283, 22620–22627
22. Combs, T. P., Wagner, J. A., Berger, J., Doebber, T., Wang, W. J., Zhang, J.

JULY 30, 2010•VOLUME 285•NUMBER 31
JOURNAL OF BIOLOGICAL CHEMISTRY 23719
Involvement of iPFK2 in the Effect of PPARγ Activation

B. B., Tanen, M., Berg, A. H., O’Rahilly, S., Savage, D. B., Chatterjee, K., Weiss, S., Larson, P. J., Gottesdiener, K. M., Gertz, B. J., Charron, M. J., Scherer, P. E., and Moller, D. E. (2002) Endocrinology 143, 998–1007

23. Tontonoz, P., and Spiegelman, B. M. (2008) Annu. Rev. Biochem. 77, 289–312

24. Tontonoz, P., Hu, E., Devine, J., Beale, E. G., and Spiegelman, B. M. (1995) Mol. Cell Biol. 15, 351–357

25. Devine, J. H., Eubank, D. W., Clouthier, D. E., Tontonoz, P., and Antoine, B. (2003) Biochem. Soc. Trans. 31, 1125–1129

26. Tontonoz, P., Hu, E., Devine, J., Beale, E. G., and Spiegelman, B. M. (2008) Cell Metabolism 9, 13604–13612

27. Pan, G. D., Debard, C., Tiraby, C., Humphreys, S. M., Frayn, K. N., Langin, D., Vidal, H., and Karpe, F. (2003) Nat. Med. 9, 811–812

28. Franckhauser, S., Muñoz, S., Elias, I., Ferre, T., and Bosch, F. (2006) Diabetes 55, 273–280

29. Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, I., Nichols, A., Ross, J. S., Tartaglia, L. A., and Chen, H. (2003) J. Clin. Invest. 112, 1821–1830

30. Permara, A. P., Zhang, W., Wabitsch, M., Fischer-Posovszky, P., Duckworth, W. C., and Reaven, P. D. (2009) Am. J. Physiol. Endocrinol. Metab. 296, E1076–E1084

31. Nielsen, R., Pedersen, T. A., Hagenbeek, D., Moulos, P., Siersbaek, R., Megens, E., Denissenov, S., Bergeisen, M., Francois, K. J., Mandrup, S., and Stunnenberg, H. G. (2008) Genes Dev. 22, 2953–2967

32. Atsumi, T., Nishio, T., Niwa, H., Takeuchi, J., Bando, H., Shimizu, C., Yoshioka, N., Bucala, R., and Koike, T. (2005) Diabetes 54, 3349–3357

33. Chesney, J., Telang, S., Yalcin, A., Clem, A., Wallis, N., and Bucala, R. (2005) Biochem. Biophys. Res. Commun. 331, 139–146

34. Hsu, Y., Guo, X., Li, H., Wang, H., Zhang, W., Wang, Y., Zhou, H., Gao, Z., Telang, S., Chesney, J., Chen, Y. F., Ye, J., Chapkin, R. S., and Wu, C. (2010) J. Biol. Chem. 285, 3713–3721

35. Wu, C., Okar, D. A., Newgard, C. B., and Lange, A. J. (2001) J. Clin. Invest. 107, 91–98

36. Wu, C., Kang, J. E., Peng, L. J., Li, H., Khan, S. A., Hillard, C. J., Okar, D. A., and Lange, A. J. (2005) Cell Metabolism 2, 131–140

37. Wu, C., Khan, S. A., Peng, L. J., Li, H., Carmella, S. G., and Lange, A. J. (2006) Am. J. Physiol. Endocrinol. Metab. 291, E536–E543

38. Zhang, J., Fu, M., Cui, T., Xiong, C., Xu, K., Zhong, W., Xiao, Y., Floyd, D., Liang, J., Li, E., Song, Q., and Chen, Y. E. (2004) Proc. Natl. Acad. Sci. U.S.A. 101, 10703–10708

39. Berger, J. I., and Barnard, R. J. (1999) J. Appl. Physiol. 87, 227–232

40. Haemmerle, G., Zimmermann, R., Hayn, M., Theussl, C., Waeg, N., Sattler, W., Magin, T. M., Wagner, E., and Zechnier, R. (2002) J. Biol. Chem. 277, 4806–4815

41. Cao, H., Gerhold, K., Meyers, J. R., Wiest, M. M., Watkins, S. M., and Hotamisligil, G. S. (2008) Cell 134, 933–944

42. Stansbie, D., Brownsey, R. W., Crettaz, M., and Denton, R. M. (1976) Biochem. J. 160, 413–416

43. Subauste, A. R., and Burant, C. F. (2007) Am. J. Physiol. Endocrinol. Metab. 293, E159–E164

44. Diaz-Delfín, J., Morales, M., and Caelles, C. (2007) Diabetes 56, 1865–1871

45. Guillemere, A., Virbasius, J. V., Puri, V., and Chen, J. P. (2008) Nat. Rev. Mol. Cell Biol. 9, 367–377

46. Greenberg, A. S., and Obin, M. S. (2006) Am. J. Clin. Nutr. 83, 461S–465S

47. Tontonoz, P., and Spiegelman, B. M. (1999) J. Biol. Chem. 274, 10703–10708

48. Weisberg, S. P., and Haffner, S. M. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 175–184

49. Lumeng, C. N., Bodzin, J. L., and Saltiel, A. R. (2007) J. Clin. Invest. 117, 175–184

50. Lumeng, C. N., Deyoung, S. M., Bodzin, J. L., and Saltiel, A. R. (2007) J. Clin. Invest. 117, 175–184

51. Kamei, N., Tobe, K., Suzuki, R., Ohsumi, M., Watanabe, T., Kubota, N., Ohtsuka-Kowatari, N., Kumagai, K., Sakamoto, K., Kobayashi, M., Yamuchi, T., Ueki, K., Oishi, Y., Nishimura, S., Manabe, I., Hashimoto, H., Ohnishi, Y., Ogata, H., Tokuyama, K., Tsunoda, M., Ide, T., Murakami, K., Nagai, R., and Kadowaki, T. (2006) J. Biol. Chem. 281, 26602–26614

52. Liumeng, C. N., Bodzin, J. L., and Saltiel, A. R. (2007) J. Clin. Invest. 117, 175–184

53. Bouhlel, M. A., Derudas, B., Rigamonti, E., Diérvart, R., Brozek, J., Haulon, S., Zawadzki, C., Jude, B., Torpier, G., Marx, N., Staels, B., and Chinet-Gbaguidi, G. (2007) Cell Metabolism 6, 137–143

54. Fujijsaka, S., Usui, I., Bukhari, A., Ikutani, M., Oya, T., Kanatani, Y., Tsunoda, M., Nagai, Y., Takatsu, K., Ureka, M., Kobayashi, M., and Tobe, K. (2009) Diabetes 58, 2574–2582